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Model calibration yielded R0= 1.1. A coverage of 50 to 75% of the 2-17 years-old with 
QLAIV averted 295,400 to 374,000 symptomatic influenza cases/year (-45% to -57% 
of the current number of cases), of which 187,000 to 242,000 cases were among 
adults ≥ 18 (due to indirect effects). Vaccinating 75% of the 2-11 years-old and 50% 
of the 12-17 years-old averted 333,200 cases/year (of which 213,000 cases/year were 
in adults). Vaccinating only healthy 2-5 years-old or only increasing the coverage of 
at-risk 2-17 children generated direct protection but only limited indirect protec-
tion even with 90% coverage: respectively 72,500 (-11%) or 37,500 (-6%) total averted 
cases/year. Sensitivity analyses showed robustness of these results. ConClusions: 
The model demonstrates both direct and indirect protection benefits of vaccinating 
healthy children with QLAIV in Belgium. Policies targeting only at-risk individuals or 
the youngest provide limited herd protection as school-age children are important 
influenza vectors due to their high contact frequencies within the community.
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objeCtives: The Highly Active Antiretroviral Treatment(HAART) expense plays 
a crucial role in managing resources properly .Aim of this work is to validate a 
scoring system that combines appropriateness, drug-spending and clinical out-
comes. Methods: All patients followed by our HIV outpatients service who started 
a first or an early switch regimen(II line) in 2014 have been enrolled. Demographic 
and epidemiological data were recorded. Each HIV treatment receives a score result-
ing from combining its relevance (according to Italian guidelines) and its related 
monthly cost. The most appropriate and less expensive regimen got a score of 1 
point, whilst other are rated declining progressively by 0,05 points according to their 
value based on the two parameters described above (range: 1-0,1). Furthermore, 
we followed the clinical course recording CD4 cell increase and HIV viral load 
decrease as a surrogate marker of quality of life. Results: 42 pts. included (29 
male); mean age : 42 years. 26 patients were in first line, 13 on early switch, 3 in 
both lines. Average treatment duration was 198 days (16-362). Mean CD4 was 270 
cc/ml for 1st line patients and 462 for early switch respectively. 11 Only 9 patients 
were classified C according to CDC criteria (A= 11; B= 26). We obtained an overall 
appropriateness score of 0,89, tenofovir-Based Single Tablet Regimens (TVD-STR) 
rated 0,99 , PI-Based Regimens got a score of 0,91. Mean monthly therapy cost was 
€ 627,3 vs. € 719,8 respectively. After three months, all patients were virologically 
suppressed. ConClusions: Our study helped in defining the APROSCE system as 
an efficacious tool to evaluate the correlation of treatment appropriateness, drug 
expense and clinical outcomes .Higher score is a predictor of better outcomes and 
less drug expenditure. Related savings might be invested in more complex patients 
management with multi drug resistant strains or AIDS presenter.
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objeCtives: A number of treatment combinations are licensed for genotype 1 (GT1) 
hepatitis C (HCV)infection. A mixed treatment comparison (MTC) is a methodological 
tool that allows estimation of the relative effectiveness of interventions that have not 
been compared directly through phase III comparative randomised controlled trials 
(RCT). The aim of this study is to indirectly estimate the relative treatment effect of 
licensed regimens for the treatment of genotype-1, treatment naïve (TN) patients with 
chronic HCV infection. Methods: A systematic review identified relevant phase II and 
III studies. Studies that evaluated licensed interferon-containing and interferon-free 
regimens for GT1 chronic HCV were included. A MTC was undertaken for an overall 
cohort of GT1, TN patients, not stratified according to genotype 1a or 1b, or the pres-
ence or absence of cirrhosis. Results were obtained by using Markov chain Monte 
Carlo simulation in OpenBugs3.2.3. Results: Two hundred and forty nine studies 
were identified of whom thirty-five met the inclusion criteria. Eight treatments were 
compared in a MTC analysis, where single-agent studies were excluded. A cumula-
tive rankogram was constructed which illustrated that the probability of sofosbuvir/
daclatasvir (SOF/DCV) being the most effective treatment was 55%. This was fol-
lowed by sofosbuvir/ledipasvir (SOF/LDV) (37%) and paritaprevir, boosted with rito-
navir, in combination with ombitasvir and dasabuvir with ribavirin (P/rOD) (6.6%). 
Incorporating additional evidence from single-agent studies and matching them with 
data from similar arms of other studies allows for the inclusion of two additional regi-
mens; daclatasvir with pegylated-interferon and ribavirin (DCV/PR) and simeprevir/
sofosbuvir (SIM/SOF). ConClusions: In this MTC, SOF/DCV is the most effective 
treatment for genotype 1, TN hepatitis C patients. In the absence of head-to-head 
trials, MTCs play a crucial role in guiding clinical decision making. The analysis from 
this study will provide relevant information on licensed regimens for the hepatitis C 
infected, genotype 1, treatment naïve patients.
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objeCtives: Recommended treatment regimens for HIV-1-infected patients com-
bine antivirals from different therapeutic classes, usually a two-drug backbone (TDF/
FTC or ABC/3TC) with a third agent from another therapeutic class. We sought to 
understand the clinical evidence differentiating these backbones in treatment-naïve 
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objeCtives: To evaluate the virological outcomes of a cohort of HIV infected 
patients started on antiretroviral treatment (ART) and followed up for 10 years in 
Uganda. Methods: The study was performed at the Infectious Diseases Institute, 
Uganda. Viral load (VL) testing was performed every 6 months. We reported propor-
tion and cumulative probability (Kaplan Meier methods) of 1) achieving viral sup-
pression (VS) (at least one VL < 400 copies/ml) 2) experiencing viral failure in patients 
who achieved suppression, (2 consecutive VL > 1000 copies or one VL> 5,000 for those 
without a subsequent VL according to WHO guidelines) We used Cox regression 
methods to determine the characteristics associated with unfavorable virological 
outcomes (no suppression or viral failure). We included gender, baseline age, WHO-
stage, body max index (BMI), CD4 count, VL and time-dependent CD4-count and 
ART-adherence. Predictors with a P-value ≤ 0.2 in the unadjusted analysis were 
included in the multivariate analysis. Results: 472/559 (84.8%) patients had at 
least one VL (67 died, 14 lost, 4 transferred, 2 no VL available). 69% were female, 
median age was 44 years (IQR: 39-51), 89.9% were in WHO-stage 3&4, median CD4 
count was 102 cell/µL (IQR:31-167), median log10 VL 5.4 (IQR:5.1-5.8); 73.6% started 
on d4T/3TC/nevirapine and 26.4% on AZT/3TC/efavirenz. 439/472 (93%) achieved VS, 
cumulative probability: 94.1% (CI:91.7-96.1). 135/439 (30.7%) experienced VF, cumula-
tive probability: 33.9 %(CI: 29.4-38.9). In the multivariate analysis initial d4T/3TC/
nevirapine (HR:1.92, CI:1.28-2.87, P< 0.001) was associated with unfavorable viral 
outcomes while patients with adherence > 95% (HR:0.12, CI:0.05-0.27) and higher 
time-dependent CD4-count (HR:0.993 per 50 cell/µL increase, CI:0.94-0.99, P< 0.001) 
were less likely to obtain an unfavorable outcome. ConClusions: Achieving and 
maintaining viral suppression is associated with reduction in mortality and mor-
bidity and it is a key factor in the strategy of using ART as treatment as prevention: 
our results are encouraging and comparable to those from resource-rich settings.
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objeCtives: A comparison of all available once-daily fixed dose STR to MTR (of 
any frequency, containing FDC) using randomized controlled trials, observational 
studies and economic models focused on adherence measures could inform HIV 
healthcare providers and policy makers regarding modalities of patient disease man-
agement to improve health outcomes. A systematic review and meta-analysis of 
published literature was conducted to compare STR to MTR. Methods: Published 
literature in English between 2005 and 2014 was searched using Embase, Medline, 
PubMed (Medline in-process) and ClinicalTrial.Gov databases. Two-level screening 
was undertaken by two independent researchers to finalize articles for evidence 
synthesis. Adherence, efficacy, safety, tolerability, HRU and costs were assessed 
comparing STR to MTR. A random effects meta-analysis was performed and 
heterogeneity examined using meta-regression. Adherence, HRU/Cost evaluations 
are summarized in this abstract. Results: Of the 39 articles identified for qualitative 
evidence synthesis, 22 reported patient adherence outcomes and 5 had quantifiable 
data for meta-analysis. STR patients were statistically significantly more adher-
ent (per respective study-defined adherence goals) compared to MTR patients of 
any frequency (Odds Ratio (OR):2.37 (95% CI:1.68, 3.35) (p < 0.001)), twice-daily MTR 
(OR:2.53 (95% CI:1.13, 5.66) and once-daily MTR (OR:1.81 (1.15, 2.84)). Several stud-
ies reported significant reduction in HRU and costs among STR group versus MTR 
(albeit, none was eligible for meta-analysis): mean costs (annual, bi-annual, monthly 
or per-diem) were found to be lower for the STR group compared to MTR, and STR was 
also deemed cost-effective, based on its lower incremental cost-effectiveness ratio 
(ICER). ConClusions: STR demonstrated significant impact on improving adherence 
and potentially lowering overall HRU and costs in comparison to MTR. These find-
ings may have policy implications for HIV disease management in resource-limited 
settings, considering the known associations between ART adherence and improve-
ments in humanistic/clinical burden among HIV patients, and the potential HRU/
cost savings associated with STRs.
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AN INtrANAsAl tetrAvAleNt lIve AtteNuAted vAccINe IN belgIum 
usINg A dyNAmIc trANsmIssIoN model
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objeCtives: To estimate the public health outcomes associated with vaccination of 
healthy Belgian children aged 2-17 years using an intranasal tetravalent live-attenu-
ated influenza vaccine (QLAIV), compared to the current coverage of at-risk/elderly 
individuals with the trivalent inactivated vaccine (TIV). Methods: A deterministic, 
age-structured, dynamic model was used to simulate influenza transmission (4 
strains) in the Belgian population, under the current coverage or after extending 
vaccination coverage to healthy children aged 2-17 with QLAIV. Differential equa-
tions describe demographic changes, exposure to infectious individuals (between-
individuals contact frequencies from the Belgian POLYMOD matrix), vaccination 
immunity dynamics, infection and recovery (parameters from international lit-
erature). The basic reproduction number (R0) was calibrated to the observation of 
285,951 influenza doctor visits/year (Belgian surveillance network). Efficacy was 
80% QLAIV vs. 59-68% TIV. The 10-year incidence of symptomatic influenza was 
calculated with different coverage scenarios (add-on to current coverage). Results: 
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associated with high therapeutic efficiency, and are expected to maximize the 
years of life of the Portuguese genotype-1 HCV patients.
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objeCtives: To estimate long-term clinical outcomes of using rilpivirine/tenofo-
vir/emtricitabine (single tablet regimen) in treatment of naïve patients with HIV-1 
RNA< 100 000 copies/ml in the Russian Federation. Methods: The mathematical 
model was developed in Microsoft Office 2013. The time horizon was 5 years. The 
model included two submodels: Markov’s model and tree-decision model. The fol-
lowing outcome measures were used in present study: Number of deaths, Years of 
life lost, Number of hospitalizations. All calculations were based on results of pub-
lished clinical, epidemiological and social researches. Data for patients with HIV was 
obtained from prior epidemiological studies that had been provided in the Russian 
Federation. Results: The number of deaths on rilpivirine/tenofovir/emtricitabine 
scheme (single tablet regimen) was 12% and 15% less, the number of YLL was 9% 
and 12% less and Number of hospitalizations was 19,91% and 19,88% less than on 
the schemes efavirenz + tenofovir/ emtricitabin (multi-pill regimen) and lopinavir 
+ tenofovir/ emtricitabin (multi-pill regimen), respectively. ConClusions: Results 
obtained with present model showed that treatment naïve patients with HIV-1 
RNA< 100 000 copies/ml using rilpivirine/tenofovir/emtricitabine scheme (single 
tablet regimen) can be associated with better long-term outcomes compared to 
alternative multi-pill schemes.
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objeCtives: E/C/F/TAF is the combination of Elvitegravir/Cobicistat/Emtricitabine 
with Tenofovir Alafenamide, a new prodrug of tenofovir with a better biodisponibil-
ity and safety profile than Tenofovir Disoproxil Fumarate (TDF) . We used adjusted 
indirect comparison to estimate the relative efficacy of E/C/F/TAF versus HAART 
based on raltegravir (RAL) or dolutegravir (DTG) in treatment-naïve HIV-1 infected 
patients that was not directly studied in head-to-head randomized controlled tri-
als. Methods: A systematic review of published literature was conducted to iden-
tify phase 3 randomized controlled clinical trials (up to February 2015) including 
at least one third agent of interest. Network adjusted indirect comparison was 
used to evaluate week 48 relative effectiveness (HIV-RNA suppression to 50 copies/
mL) after checking for homogeneity and absence of interaction between baseline 
characteristics and efficacy. Analyses based on secondary networks were performed 
to assess validity. A ten percent margin was used for non-inferiority. Results: 
Twelve studies were included in the network. Baseline patient’s characteristics were 
slightly different between studies published before and after 2011 due to changes in 
2011 in treatment initiation guidelines. No significant interactions were observed 
in the studies between baseline characteristics and week 48 virologic suppression. 
E/C/F/TAF was associated with a non-significant different rate for week 48 virologic 
suppression compared to DTG + ABC/3TC or RAL + TDF/FTC (Relative Risk = 0.98 
(0.89 - 1.07) and 1.01 (0.92 - 1.12) respectively). Using secondary networks yielded 
similar results. ConClusions: This indirect comparison suggests that with ten 
percent non-inferiority margin E/C/F/TAF has a similar efficacy then DTG or RAL 
based HAART.
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objeCtives: Trivalent influenza vaccine (TIV), which contains two strains of 
influenza A and one strain of influenza B is recommended by the Brazilian gov-
ernment to prevent influenza. However, co-circulation of two distinct B lineages 
and difficulties in predicting which lineage will predominate in the next season 
led to the development of quadrivalent influenza vaccine (QIV). The aim of the 
study was to estimate the public health (epidemiological) and economic impact 
of the QIV over four influenza seasons (2010 to 2013) in the Brazilian population 
in comparison with TIV. Methods: A static model published by Reed et al. in 
2012 was adapted to Brazil and stratified by age group. The model retrospectively 
calculated impact using vaccine effectiveness and coverage, illness incidence, 
morbidity, mortality and costs related to influenza from the Public Healthcare 
System and Society perspectives. Vaccine effectiveness by strain and by age in 
the Brazilian population is not available; therefore we used vaccine effectiveness 
from Clements et al., which takes into account some B-lineage cross-protection. 
Epidemiological and resource use data were obtained from the Brazilian pub-
lic system database (DATASUS) and regional studies. Costs were expressed in 
2015 Brazilian Real, vaccine cost was not considered and exchange rate used was 
$1.00USD= 3.14BRL. Results: The use of QIV vaccination instead of TIV in the 
years from 2010 to 2013 would have avoided a total of additional 654,018 cases, 
323,336 consultations, 7,536 hospitalizations and 1,122 deaths due to influenza. In 
2013, year with high B circulation and high mismatch, considering a public payer 
and societal perspective, respectively, QIV vaccination could have avoided addi-
tional influenza costs estimated at BRL 11 million and 62 million (USD 3.5 million 
and 20 million). ConClusions: Vaccination with QIV for the Brazilian population 
is expected to result in public health benefit and less resource use when compared 
to TIV.
patients. Methods: A SLR identified randomised controlled trials (RCTs) of TDF/
FTC or ABC/3TC plus third agents grouped by class (protease inhibitors [PI], non-
nucleoside reverse transcriptase inhibitors [NNRTI] and integrase strand transfer 
inhibitors [INSTI]) in HIV-1 infection. MEDLINE, EMBASE and the Cochrane Library 
were searched in March 2014. Bayesian NMAs of RCTs in were run for virologic 
response (VR) and all-cause discontinuation at Week 48 (Wk48) and 96 (Wk96). 
Inconsistency and the effect of baseline characteristics were also assessed using 
unrelated mean-effects models and meta-regression, respectively. Results: Of 
1,093 citations retrieved, 243 citations were included in the SLR, reporting 18 RCTs 
that informed at least one network. In the NMA, fixed-effect models represented 
a better fit for VR data, whereas random-effects models fitted the all-cause dis-
continuation data best. With NNRTIs, TDF/FTC was associated with significantly 
higher odds of VR than ABC/3TC at Wk48 (OR 1.32 [95%CrI 1.05, 1.65]) and Wk96 
(OR 1.29 [95%CrI 1.03, 1.61]). With INSTIs, TDF/FTC had a significantly higher odds 
of VR at Wk96 compared with ABC/3TC (OR 1.46 [95%CrI 1.04, 2.04]). No statistically 
significant differences in VR were found between the backbones with PIs. No sta-
tistically significant differences in all-cause discontinuation at Wk48 or Wk96 were 
observed between the backbones with any class of third agent. Networks showed 
little inconsistency, and baseline characteristics did not have any significant effect 
on results. ConClusions: TDF/FTC was associated with statistically significant 
VR benefits compared with ABC/3TC with NNRTIs at both Wk48 and Wk96 and 
with INSTIs at Wk96, and no statistically significant effect was seen with respect 
to all-cause discontinuation.
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objeCtives: There is no consistent evidence of clinical efficacy of IgM-enriched 
intravenous immunoglobulin (IgM) for reducing mortality in adults, newborns and 
older children with bacterial infections and sepsis. The aim of the study was to 
update evidence by considering recent clinical trials and analyzing age popula-
tions and comparators separately. Methods: We searched publications in PubMed 
and the Cochrane Library in December 2014. All-cause mortality was analyzed, 
and systematic review using meta-analysis and indirect comparison was carried 
out. Results: Five meta-analyses and 18 RCTs were considered, including 12 trials 
studied the effect of IgM in adults, 5 in newborns, and one in children 1-24 months 
old. All interventions were applied with basic therapy (BT). No difference between 
IgM and albumin was found for adults. However we found significant efficacy of 
IgM in adults when compared with all comparators, RR 0.69 [0.56; 0.84], and BT, 
RR 0.52 [0.39; 0.69]. In newborns mortality is lower in IgM than in all comparators 
groups, RR 0.47 [0.29; 0.76], and in BT with or without placebo, RR 0.50 [0.30; 0.84]. 
Children under 24 months receiving IgM also had lower mortality than in all com-
parators group, RR 0.48 [0.34; 0.68]. Indirect comparison of IgM and IgG in adults 
showed no differences, in newborns the difference is in favor of IgM, RR 0.47 [0.29; 
0.77]. ConClusions: IgM is effective in reducing all-cause mortality in adults with 
bacterial infection or sepsis in comparison with BT; also in newborns in comparison 
with any comparators (BT with or without placebo, albumin, IgG), in children under 
24 months in comparison to BT with or without albumin. Further head-to-head 
clinical trials are needed to enhance evidence.
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objeCtives: Chronic hepatitis C (CHC) is a major public health problem affecting 
1.5% of the Portuguese population and reducing life expectancy by 20 years. The 
most recent international guidelines recommend the utilization of sofosbuvir 
(SOF) as backbone for the treatment of CHC patients. The association of ledipasvir 
(LDV) to SOF enhances SOF efficacy and safety, especially in patients infected with 
genotype-1 hepatitis C virus. Additionally, it allows the treatment of CHC patients 
without using pegylated interferon-α (PegIFN) and ribavirin (RBV). The objective of 
this study was to estimate LDV/SOF’s contribution to the Portuguese public health 
by exhausting CHC therapeutic efficiency. Methods: Therapeutic efficiency was 
defined as maximum capacity to benefit from treatment in terms of life years 
(LY) relative to the general population’s life expectancy. The natural history of 
CHC and treatment implication was modelled with a Markov model allowing for 
long-term assessment in terms of HCV fibrosis progression. Comparators used 
were SOF+PegIFN+RBV, SOF+RBV, boceprevir+PegIFN+RBV and PegIFN+RBV, taking 
into consideration the therapeutic options currently financed by the Portuguese 
National Health System, the recommendation of SOF as the standard of care and 
the coincidence between therapeutic indications. Results: In HCV genotype-1 
non-cirrhotic patients, LDV/SOF treatment is estimated to result in 0.21 LY, 1.5 LY 
or 1.44-2.90 LY gained in comparison to SOF+PegIFN+RBV, SOF+RBV or the options 
financed by the Portuguese NHS, respectively; for patients with cirrhosis, these 
values are 1.20 LY, 4.08 LY or 1.33-4.67 LY, respectively. In patients infected with 
HCV genotype-1, LDV/SOF is expected to enhance life expectancy, with therapeutic 
efficiency ranging from 86.2% to 98.4%. ConClusions: LDV/SOF regimens are 
